{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:25Z","timestamp":1791976105561,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,25]]},"DOI":"10.7759\/cureus.19024","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:34:55Z","timestamp":1635161695000},"source":"Crossref","is-referenced-by-count":5,"title":["Dasatinib-Induced Pleural and Pericardial Effusions"],"prefix":"10.7759","author":[{"given":"Yousef  M","family":"Hailan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali PA","year":"2016","unstructured":"Pophali PA, Patnaik MM. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 2016, 22:40-50. 10.1097\/PPO.0000000000000165","journal-title":"Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/11207580-000000000-00000","article-title":"Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"71","author":"McCormack PL","year":"2011","unstructured":"McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011, 71:1771-95. 10.2165\/11207580-000000000-00000","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama A","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007, 25:3908-14. 10.1200\/JCO.2007.12.0329","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"Lavallade HD","year":"2008","unstructured":"Lavallade HD, Punnialingam S, Milojkovic D, et al.. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008, 141:745-7.","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.032","article-title":"Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume","volume":"23","author":"Jayson GC","year":"2005","unstructured":"Jayson GC, Parker GJ, Mullamitha S, et al.. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol. 2005, 23:973-81. 10.1200\/JCO.2005.01.032","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0110-4","article-title":"Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors","volume":"4","author":"Kelly K","year":"2009","unstructured":"Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009, 4:99-105. 10.1007\/s11523-009-0110-4","journal-title":"Target Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron A","year":"2007","unstructured":"Bergeron A, R\u00e9a D, Levy V, et al.. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007, 176:814-8. 10.1164\/rccm.200705-715CR","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka K","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010, 116:377-86. 10.1002\/cncr.24734","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour E","year":"2011","unstructured":"Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011, 25:201-10. 10.1038\/leu.2010.215","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-46","article-title":"The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib","volume":"2","author":"Masiello D","year":"2009","unstructured":"Masiello D, Gorospe G 3rd, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol. 2009, 2:46. 10.1186\/1756-8722-2-46","journal-title":"J Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.040048","article-title":"Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy","volume":"96","author":"Eskazan AE","year":"2011","unstructured":"Eskazan AE, Soysal T, Ongoren S, Gulturk E, Ferhanoglu B, Aydin Y. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011, 96:e15; author reply e16-7. 10.3324\/haematol.2011.040048","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily","volume":"96","author":"Krauth MT","year":"2011","unstructured":"Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schl\u00f6gl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011, 96:163-6. 10.3324\/haematol.2010.030494","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i1.8914","article-title":"Dasatinib induced pleuro-pericardial effusion","volume":"91","author":"Mishra AK","year":"2020","unstructured":"Mishra AK, Sahu KK, Kaul S, Lal A. Dasatinib induced pleuro-pericardial effusion. Acta Biomed. 2020, 91:142-3. 10.23750\/abm.v91i1.8914","journal-title":"Acta Biomed"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2017\/24633.9418","article-title":"Dasatinib induced cardiac tamponade-a rare association","volume":"11","author":"Wattal S","year":"2017","unstructured":"Wattal S, Rao MS, Chandra GN, Razak UK, Shetty KR. Dasatinib induced cardiac tamponade-a rare association. J Clin Diagn Res. 2017, 11:FD03-4. 10.7860\/JCDR\/2017\/24633.9418","journal-title":"J Clin Diagn Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah NP","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, et al.. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008, 26:3204-12. 10.1200\/JCO.2007.14.9260","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.4440.4440","article-title":"Efficacy and safety of dasatinib 50 mg once daily dose in patients with chronic phase CML who failed imatinib","volume":"118","author":"Yassin MA","year":"2011","unstructured":"Yassin MA, El Ayoubi HR. Efficacy and safety of dasatinib 50 mg once daily dose in patients with chronic phase CML who failed imatinib. Blood. 2011, 118:4440. 10.1182\/blood.V118.21.4440.4440","journal-title":"Blood"},{"key":"ref17","article-title":"Common terminology criteria for adverse events (CTCAE)","author":"U.S. Department of Health and Human Services","year":"2017","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). U.S. Department of Health and Human Services, Washington, DC; 2017."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133904","article-title":"Association of tuberculosis in patients with chronic myeloid leukemia, a treatment proposal based on literature review","volume":"136","author":"Iqbal P","year":"2020","unstructured":"Iqbal P, Yassin M, Soliman A, Desanctis V. Association of tuberculosis in patients with chronic myeloid leukemia, a treatment proposal based on literature review. Blood. 2020, 136:28-9. 10.1182\/blood-2020-133904","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181ae9227","article-title":"Dasatinib-induced pleural effusions: a lymphatic network disorder?","volume":"338","author":"Goldblatt M","year":"2009","unstructured":"Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA. Dasatinib-induced pleural effusions: a lymphatic network disorder?. Am J Med Sci. 2009, 338:414-7. 10.1097\/MAJ.0b013e3181ae9227","journal-title":"Am J Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2020","article-title":"Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia","volume":"31","author":"Latagliata R","year":"2013","unstructured":"Latagliata R, Breccia M, Fava C, et al.. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013, 31:103-9. 10.1002\/hon.2020","journal-title":"Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/67025-dasatinib-induced-pleural-and-pericardial-effusions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:53Z","timestamp":1707507353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/67025-dasatinib-induced-pleural-and-pericardial-effusions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.19024","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}